The way pharma teams engage with key opinion leaders (KOLs) and other stakeholders is evolving—fast. It’s no longer enough to simply schedule advisory boards in the lead-up to launch and engage the same tried-and-tested experts. Teams are looking for smarter, more scalable approaches to KOL engagement in pharma launches—and they’re even rethinking how they identify those KOLs in the first place.
In this article, we’ll explore the tools, technologies, and techniques that are helping pharma teams gather and activate critical insights from key opinion leaders, leading to more in-depth launch intelligence.
Expert ID: from narrow to broad
Historically, identifying key opinion leaders (KOLs) for an advisory board was as simple as consulting PubMed and looking for authors who had recently published in a relevant area. In the past, KOL engagements inevitably involved those experts who published most frequently, or spoke most regularly at medical congressesIn other words, the loudest voices. There are several issues with this approach:
- Publication and congress speaker data capture only a small fraction of experts within a disease community.
- The same experts are engaged repeatedly, leading to stale intelligence.
- Competitors often work with the same KOLs, resulting in identical insights.
- Diversity suffers, limiting the range of perspectives in launch planning.
- Less traditional voices—such as emerging leaders and digital opinion influencers—are often overlooked, despite their significant impact on disease community conversations.
“Our internal data has shown that if you’re only doing KOL ranking via traditional methods, somewhere between 20% and 60% of the people that come up aren’t the best people.” –Lance Hill, CEO, Within3
Today, there’s growing recognition that life science discourse has moved to online spaces. Publication volumes and speaker engagements are still important metrics, but disease communities are equally active on social media, blogs, online forums, and chat rooms. The profiles of the experts themselves have changed, too. Now, they aren’t always even HCPs – they might be patients themselves, their families, patient advocates, or digital influencers.
Pharma teams are moving to engage this new breed of experts through an approach to expert identification that uses network analytics to find the hidden connections between individuals and institutions. AI-powered network analytics helps to uncover previously-unknown spheres of influence capable of making or breaking a new therapy—unlocking a powerful new approach to KOL engagement for pharma teams.
KOL engagement: from one-off to continuous
Having identified the best KOLs to engage during their launch activities, teams are recognizing that the traditional approach to KOL engagement—scheduling a series of in-person advisory boards—is no longer suitable for gathering and activating key insights. A collection of new tools and technologies are helping to transform stakeholder engagement from a rigid, one-off process to a continuous model capable of driving informed decision-making and delivering powerful launch intelligence.
“Digital tools enable MSLs to distill complex scientific information into easily understandable bite-size content, thereby fostering clearer communication with KOLs, and improving retention of information. This not only strengthens the MSL-KOL relationship but also ensures that the most accurate and pertinent information is conveyed, thereby promoting evidence-based decision-making in healthcare.” –The MSL Journal
Asynchronous engagement
The traditional approach to KOL engagement involves scheduling in-person advisory boards that must account for a wide variety of schedules and work locations. Many KOLs drop out due to lack of availability, while others (like those located in other nations) are simply unable to participate in person.
Asynchronous virtual engagement allows advisors and other stakeholders to engage continuously, and at a time and place that works for them. Teams can capture KOL data on an ongoing basis as participants respond to questions and discussion topics according to their own schedule. Asynchronous virtual engagement platforms feature:
- Anonymized profiles to eliminate bias and peer influence
- In-platform translation so all participants can engage in their language of choice
- Real-time AI analysis to summarize key points and refine the conversation
- Intelligent prompts to help focus the discussion
These features work in tandem to offer 3-7x more feedback and up to 40% more novel insights than in-person advisory boards (according to Within3 research).
Real-time data and reporting
Actionable launch intelligence is not built on KOL engagement alone. The insights teams gather from HCPs and other key stakeholders must be complemented by other real-world signals that either support or challenge that information: social data, field activity data and MSL reports, congress data, market information, and more.
Combining real-time insights with KOL engagement helps to paint a more complete picture of a disease community, and the market any new therapy will launch into. AI-supported data integration and analysis transforms this process from a months-long activity to one that can be completed in just minutes. Teams get critical launch intelligence that aligns with their go-to-market strategy – allowing them to act quickly and decisively as market forces dictate.
“It’s about leveraging AI to continue to monitor your strategy as new data comes in, new data sets get refreshed, and you march towards your strategy and your go-to-market plans. What’s shifting in the sands beneath your feet that requires a pivot or a change?”-Jason Smith, Chief Technology Officer, AI & Analytics, Within3
In summary
KOL engagement is moving from a series of disconnected touchpoints to a continuous, connected model that delivers actionable intelligence pre-, peri-, and post-launch. Tools and technologies such as network analytics, asynchronous virtual engagement, and real-time data and reporting are driving this transformation. Experience this change for yourself: schedule a demo of the Within3 Launch Intelligence Platform today.